Pharmaceutical Technology on MSN

High-value oncology deals drive China’s drug licensing boom

China’s focus on first or best-in-class oncology drugs and innovative R&D will position it well in 2026 and beyond.
The Pharma Letter

BRIEF—FDA approves Jansen’s Akeega for mCSPC

On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...